Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting [Yahoo! Finance]
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight [Yahoo! Finance]
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases [Yahoo! Finance]